Sign in
4

Changes in Ownership

IONIS PHARMACEUTICALS INC Filed Acc 0000874015-26-000208

EVP, Chief Development Officer sold 60,846 shares at an average $73.41 ($4,466,428)

  • EVP, Chief Development Officer acquired 60,846 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kordasiewicz Holly B. · EVP, Chief Development Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2026-06-12 Exercise or conversion : show line 1 in the form 10b5-1 +7,951 $60.89 $484,136 30,409 D
2026-06-12 Exercise or conversion : show line 2 in the form 10b5-1 +21,000 $60.89 $1,278,690 51,409 D
2026-06-12 Exercise or conversion : show line 3 in the form 10b5-1 +12,000 $32.60 $391,200 63,409 D
2026-06-12 Exercise or conversion : show line 4 in the form 10b5-1 +19,895 $56.78 $1,129,638 83,304 D
2026-06-12 Sale : show line 5 in the form 10b5-1 −41,004 $73.09 $2,997,122 42,300 D
2026-06-12 Sale : show line 6 in the form 10b5-1 −19,842 $74.05 $1,469,306 22,458 D
Open-market sales · 60,846 sh · avg $73.41 · $4,466,428

Table II: Derivative

4 lines
Date Transaction Shares Owned after D/I
2026-06-12 Exercise or conversion : show line 7 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −12,000 0 D
2026-06-12 Exercise or conversion : show line 8 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −19,895 0 D
2026-06-12 Exercise or conversion : show line 9 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −7,951 21,000 D
2026-06-12 Exercise or conversion : show line 10 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −21,000 0 D
Loading xslF345X06/edgardoc.xml…